Our Current Projects
The academic research program within this laboratory is concerned with defining the key molecular interactions underlying receptor recognition events that are the primary determinants of innate and adaptive immunity. The laboratory’s research has provided an understanding of the basis of peptide, metabolite and lipid presentation, T-cell triggering, aberrant T-cell reactivity, monomorphic and polymorphic Natural Killer (NK) receptor recognition.
The team’s research on anti-viral immunity has provided an understanding of the factors that shape MHC-restriction (e.g. Immunity, 2003, 2016; Nature Immunol, 2005, 2007, 2015; Nature Rev Immunol 2018). Moreover, we have demonstrated how the preTCR, a receptor crucial for T-cell development, functions by autonomous dimerization (Nature, 2010). In relation to aberrant T-cell reactivity, our team has provided insight into alloreactivity (Immunity, 2009), Celiac Disease (Immunity, 2012; NSMB, 2014; Cell 2019) and HLA-linked drug hypersensitivities (Nature, 2012; NSMB 2014). Regarding innate and innate-like recognition, the team has shed light into how Natural Killer cell receptors interact with their cognate ligands (Nature 2011; J. Exp. Med. 2008, 2016; Nature Immunol 2013; NSMB 2017; Cell 2017; PNAS 2018).
Further, we have provided fundamental insight into how T cells recognise lipid-based antigens in the context of protective and aberrant immunity (Nature, 2007; Nature Immunol 2010, 2011, 2012, 2015, 2016, 2018; Nature Comms. 2016). Most recently, our team identified the long sought after ligand for MAIT cells, namely showing that MAIT cells are activated by metabolites of vitamin B (Nature 2012, 2014; Nat Commun 2012; Nat Immunol 2016, 2017, 2020). The industrial research program of the laboratory includes a close collaboration with Janssen (one of the Pharmaceutical companies of Johnson & Johnson), for the development of new therapies to treat Celiac Disease; and Immutep, to enhance our understanding of T-cell signalling and the development of innovative biotechnology products.